258 related articles for article (PubMed ID: 20869827)
1. Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers.
Tamada T; Ito K; Sone T; Kanki A; Sato T; Higashi H
Eur J Radiol; 2011 Dec; 80(3):e207-11. PubMed ID: 20869827
[TBL] [Abstract][Full Text] [Related]
2. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.
Tamada T; Ito K; Higaki A; Yoshida K; Kanki A; Sato T; Higashi H; Sone T
Eur J Radiol; 2011 Dec; 80(3):e311-6. PubMed ID: 21315529
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
[TBL] [Abstract][Full Text] [Related]
4. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver.
Tamada T; Ito K; Yoshida K; Kanki A; Higaki A; Tanimoto D; Higashi H
Eur J Radiol; 2011 Dec; 80(3):e284-8. PubMed ID: 21296514
[TBL] [Abstract][Full Text] [Related]
6. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
[TBL] [Abstract][Full Text] [Related]
7. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging.
Higaki A; Tamada T; Sone T; Kanki A; Sato T; Tanimoto D; Higashi H; Ito K
Magn Reson Imaging; 2012 Jun; 30(5):689-93. PubMed ID: 22459437
[TBL] [Abstract][Full Text] [Related]
8. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
9. Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis.
Kanki A; Tamada T; Higaki A; Noda Y; Tanimoto D; Sato T; Higashi H; Ito K
Magn Reson Imaging; 2012 Apr; 30(3):356-60. PubMed ID: 22227353
[TBL] [Abstract][Full Text] [Related]
10. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
[TBL] [Abstract][Full Text] [Related]
11. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA.
Frericks BB; Loddenkemper C; Huppertz A; Valdeig S; Stroux A; Seja M; Wolf KJ; Albrecht T
AJR Am J Roentgenol; 2009 Oct; 193(4):1053-60. PubMed ID: 19770329
[TBL] [Abstract][Full Text] [Related]
12. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
14. Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla.
Verloh N; Haimerl M; Rennert J; Müller-Wille R; Nießen C; Kirchner G; Scherer MN; Schreyer AG; Stroszczynski C; Fellner C; Wiggermann P
Eur J Radiol; 2013 Oct; 82(10):1710-5. PubMed ID: 23806531
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
16. Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI.
Péporté AR; Sommer WH; Nikolaou K; Reiser MF; Zech CJ
Eur J Radiol; 2013 Mar; 82(3):e101-6. PubMed ID: 23159401
[TBL] [Abstract][Full Text] [Related]
17. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI.
Tsuda N; Okada M; Murakami T
Eur J Radiol; 2010 Jan; 73(1):137-42. PubMed ID: 19026502
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
Feuerlein S; Gupta RT; Boll DT; Merkle EM
Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
[TBL] [Abstract][Full Text] [Related]
19. Primovist, Eovist: what to expect?
Van Beers BE; Pastor CM; Hussain HK
J Hepatol; 2012 Aug; 57(2):421-9. PubMed ID: 22504332
[TBL] [Abstract][Full Text] [Related]
20. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA.
Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S
J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
